Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

dures, and there is currently not a good solution for this challenging lesion subset."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. Fo
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/22/2014)... to trauma, illness, alcohol or other drug abuse, these ... cells that can go awry and activate conditions such ... autism. , Until now, it has been unclear how ... developing brain. Past studies have shown that when an ... or she experiences some trauma or illness, her baby ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
(Date:4/22/2014)... 2014) Older parents are more likely to have ... than are younger parents. A recent study from researchers ... Philadelphia and Karolinska Institute in Sweden provides more insight ... between mothers, and fathers, ages, and found that the ... intellectual disability is larger for older parents., In the ...
(Date:4/22/2014)... NH, 4/22/14). Dartmouth researchers have found that the ... and does not negatively impact a woman,s overall ... False-Positive Screening Mammograms," which was published online in ... , Anywhere from 40 to 60 percent ... a ten-year period will experience a false-positive mammogram. ...
(Date:4/22/2014)... New research published today out of the University of ... promote growth in damaged nerve cells as a means ... his team have discovered a key molecule that directly ... His study was published in the prestigious journal ... and Anand Krishnan. , "We made the surprising ...
Breaking Medicine News(10 mins):Health News:Life stressors trigger neurological disorders, researchers find 2Health News:Two genes linked to inflammatory bowel disease 2Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... loss of the four sick public sector pharmaceutical and ... the railways and the armed forces have been asked ... making units. ,According to the ministry of ... Pharmaceuticals Limited, Hindustan Insecticides Limited and Hindustan Organic Chemicals ...
... have developed a new electro-chemical biosensor, which detects the ... the most widely used herbicides in agriculture and ... environment as well as antibiotics in food. ... the expensive laboratory methods, which are used to detect ...
... Recent studies have indicated that the protein known as ... levels of TRPM8 have been found in prostate ... has been suggested as a specific marker and therapeutic ... changes in TRPM8 during prostate cancer progression have remained ...
... of people made a beeline for guru Ramdev's six-day yoga ... has been specially prepared on the outskirts of this popular ... ,Organisers said some 10,000 people, including Himachal Pradesh ... ,The state transport department has made special arrangements to ...
... has given a green signal for plantation of rise ... in Kansas. ,This is the first ... human proteins will be grown on a large-scale. ... California, the rice strains produce lysozyme, lactoferrin, and human ...
... found that full brain development in adolescents takes place between ... National Institutes of Health (NIH) MRI Study of Normal Brain ... and behaviour from birth to young adulthood. ,The ... of Psychiatry at Childrens Hospital Boston, focused on cognition and ...
Cached Medicine News:Health News:Government Hospitals to the Rescue of Loss-making Pharma Companies 2Health News:New Electro-chemical Biosensor to Check Food Contamination 2Health News:Adolescents Brains Fully Develop Between 10-12 Years 2
Lorgnette pinhole occluder...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: